tetano
Editor, Senior Moderator
Sci Rep
. 2025 May 23;15(1):18039.
doi: 10.1038/s41598-025-02212-7. Cardiac risk in recovered Covid-19 patients evaluated by [SUP]123[/SUP]I-mIBG
Alessandro Liebich[SUP] 1 2 [/SUP], Gabriel Sheikh[SUP] 3 [/SUP], Ralph A Bundschuh[SUP] 4 [/SUP], Malte Kircher[SUP] 4 [/SUP], Alexander Dierks[SUP] 4 [/SUP], Bernd Nittbaur[SUP] 4 [/SUP], Philip Raake[SUP] 5 [/SUP], Maximilian Rieger[SUP] 5 [/SUP], Takahiro Higuchi[SUP] 6 [/SUP], Christian H Pfob[SUP] 4 [/SUP], Constantin Lapa[SUP] 4 [/SUP]
Affiliations
To determine whether cardiac sympathetic nervous dysfunction is present, in this single center prospective, non-randomized trial non-invasive SPECT/CT imaging using the radiotracer [SUP]123[/SUP]I-metaiodobenzylguanidine was performed in 33 recovered COVID-19 patients without pre-existing cardiac conditions. Increased cardiac sympathetic activity, as indicated by late HMR, was observed in 67.7% of patients. At 6-8 months, 82% of these subjects (27/33) received follow-up, and cardiac sympathetic innervation abnormalities were still present in 70.4% (19/27). Additionally, at 12-15 months post-diagnosis, persistently abnormal HMRs were found in 9 individuals who initially had abnormal sympathetic innervation. Further follow-up is needed to investigate potential long-term cardiovascular consequences of COVID-19.
. 2025 May 23;15(1):18039.
doi: 10.1038/s41598-025-02212-7. Cardiac risk in recovered Covid-19 patients evaluated by [SUP]123[/SUP]I-mIBG
Alessandro Liebich[SUP] 1 2 [/SUP], Gabriel Sheikh[SUP] 3 [/SUP], Ralph A Bundschuh[SUP] 4 [/SUP], Malte Kircher[SUP] 4 [/SUP], Alexander Dierks[SUP] 4 [/SUP], Bernd Nittbaur[SUP] 4 [/SUP], Philip Raake[SUP] 5 [/SUP], Maximilian Rieger[SUP] 5 [/SUP], Takahiro Higuchi[SUP] 6 [/SUP], Christian H Pfob[SUP] 4 [/SUP], Constantin Lapa[SUP] 4 [/SUP]
Affiliations
- PMID: 40410298
- PMCID: PMC12102354
- DOI: 10.1038/s41598-025-02212-7
To determine whether cardiac sympathetic nervous dysfunction is present, in this single center prospective, non-randomized trial non-invasive SPECT/CT imaging using the radiotracer [SUP]123[/SUP]I-metaiodobenzylguanidine was performed in 33 recovered COVID-19 patients without pre-existing cardiac conditions. Increased cardiac sympathetic activity, as indicated by late HMR, was observed in 67.7% of patients. At 6-8 months, 82% of these subjects (27/33) received follow-up, and cardiac sympathetic innervation abnormalities were still present in 70.4% (19/27). Additionally, at 12-15 months post-diagnosis, persistently abnormal HMRs were found in 9 individuals who initially had abnormal sympathetic innervation. Further follow-up is needed to investigate potential long-term cardiovascular consequences of COVID-19.